Synexus Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Synexus Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013193
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Synexus Ltd (Synexus), a subsidiary of Synexus Clinical Research Limited, is a site management organisation that offers patient recruitment and trial management services. The company services include feasibility assessment, project management, patient engagement, patient-centric clinical trials, patient retention and others. Its therapeutic expertise spans across areas including CNS, allergy symptoms, asthma, copd, smoking cessation, sinusitis, obesity, endocrine disorders, cardiovascular, gout, osteoarthritis, osteopenia, osteoporosis, rheumatoid arthritis, dermatology, type I diabetes, diabetic foot ulcers and screenable medical conditions. Synexus undertakes clinical trials from phase II to IV. It has presence in Poland, Hungary, Ukraine, Germany, Romania, Bulgaria, South Africa and the US. Synexus is headquartered in Chorley, Lancashire, the UK.

Synexus Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Synexus Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Synexus Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Synexus Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Synexus Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Synexus Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Synexus Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Synexus Acquires Clinical Trial Site 10
Private Equity 11
LDC Acquires Synexus in Management Buy-Out Transaction for USD127.7 Million 11
Acquisition 12
LDC Divests Synexus Clinical Research for USD258 Million 12
Synexus Acquires Research Across America 13
Synexus Acquires Centrum Medyczne Osteomed, Clinical Research Company 14
Adcock Ingram Acquires Remaining 49% Stake In AddClin Research From Synexus 15
Synexus Ltd – Key Competitors 16
Synexus Ltd – Key Employees 17
Synexus Ltd – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Synexus Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Synexus Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Synexus Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Synexus Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Synexus Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Synexus Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Synexus Acquires Clinical Trial Site 10
LDC Acquires Synexus in Management Buy-Out Transaction for USD127.7 Million 11
LDC Divests Synexus Clinical Research for USD258 Million 12
Synexus Acquires Research Across America 13
Synexus Acquires Centrum Medyczne Osteomed, Clinical Research Company 14
Adcock Ingram Acquires Remaining 49% Stake In AddClin Research From Synexus 15
Synexus Ltd, Key Competitors 16
Synexus Ltd, Key Employees 17
Synexus Ltd, Other Locations 18
Synexus Ltd, Subsidiaries 19

★海外企業調査レポート[Synexus Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kuwait Petroleum International Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Kuwait Petroleum International Ltd (KPI), a subsidiary of Kuwait Petroleum Corporation, is a downstream energy company. It carries out refining of crude oil, production and marketing of refined petroleum products. The company operates refinery in Milazzo, Italy, and has retail service statio …
  • Bell Helicopter Textron Inc.:企業の戦略・SWOT・財務情報
    Bell Helicopter Textron Inc. - Strategy, SWOT and Corporate Finance Report Summary Bell Helicopter Textron Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • GS Retail Co., Ltd. (007070):企業の財務・戦略的SWOT分析
    GS Retail Co., Ltd. (007070) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • FBN Bank (UK) Ltd:企業の戦略・SWOT・財務情報
    FBN Bank (UK) Ltd - Strategy, SWOT and Corporate Finance Report Summary FBN Bank (UK) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Digital Realty Trust Inc:企業のM&A・事業提携・投資動向
    Digital Realty Trust Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Digital Realty Trust Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Amarin Corp Plc (AMRN)-製薬・医療分野:企業M&A・提携分析
    Summary Amarin Corp Plc (Amarin) is a biopharmaceutical company which develops and commercializes medicines for cardiovascular domain. The company's lead product Vascepa (icosapent ethyl) is a US FDA approved single-molecule prescription capsule used as an adjunct to diet, for the reduction of trigl …
  • Circle Pharma Inc-製薬・医療分野:企業M&A・提携分析
    Summary Circle Pharma Inc. (Circle Pharma) is a drug development company that strives to develop cell permeable macrocyclic peptide therapies by combining computational design and synthetic chemistry. Its technology platform is applicable in a wide range of disease conditions such as fibrosis, infla …
  • PT Perusahaan Listrik Negara (Persero) Tbk:戦略・SWOT・企業財務分析
    PT Perusahaan Listrik Negara (Persero) Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Perusahaan Listrik Negara (Persero) Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • AmpliPhi Biosciences Corp (APHB):製薬・医療:M&Aディール及び事業提携情報
    Summary AmpliPhi Biosciences Corp (AmpliPhi) is a biotechnology company which focuses on development and commercialization of bacteriophage-based antibacterial therapeutics. The company by utilizing its proprietary bacteriophage technology developed a pipeline of products for the treatment of variou …
  • Stanmore Coal Ltd:企業の戦略・SWOT・財務分析
    Stanmore Coal Ltd - Strategy, SWOT and Corporate Finance Report Summary Stanmore Coal Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Domino’s Pizza, Inc.:企業の戦略・SWOT・財務情報
    Domino's Pizza, Inc. - Strategy, SWOT and Corporate Finance Report Summary Domino's Pizza, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Centrose LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Centrose LLC (Centrose) is a precision drug company that develops medicines to target diseased tissues. The company's product pipeline includes EDC1 (Dysadherin), EDC2 (CD147), EDC3 (CD98), EDC5 (CD44), and EDC8 (CD38). Its product EDC1 combines two proteins found in close proximity to treat …
  • MyoKardia Inc (MYOK):企業の財務・戦略的SWOT分析
    MyoKardia Inc (MYOK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Energia Argentina SA:電力:M&Aディール及び事業提携情報
    Summary Energia Argentina SA (ENARSA) is a state owned energy company that explores and exploits hydrocarbons in solid, liquid and gaseous states. It stores, transports, distributes, markets and industrializes the hydrocarbons and their derivatives. Energia conducts design, construction, commissioni …
  • DAMAC Real Estate Development Ltd:企業の戦略・SWOT・財務情報
    DAMAC Real Estate Development Ltd - Strategy, SWOT and Corporate Finance Report Summary DAMAC Real Estate Development Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • SMRT Corporation Ltd.:戦略・SWOT・企業財務分析
    SMRT Corporation Ltd. - Strategy, SWOT and Corporate Finance Report Summary SMRT Corporation Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Grasim Industries Ltd (GRASIM):企業の財務・戦略的SWOT分析
    Grasim Industries Ltd (GRASIM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Bioderm Inc:医療機器:M&Aディール及び事業提携情報
    Summary Bioderm Inc (Bioderm) is a medical equipment company that manufactures designs, and markets hydrocolloid products. The company manufactures hydrocolloid products for urinary management, securement, infection control, and skin protection. Its products include cathgrip, bioplus+, freederm, men …
  • EndoGastric Solutions Inc-製薬・医療分野:企業M&A・提携分析
    Summary EndoGastric Solutions Inc (EGS), formerly EsophyX, Inc. is a medical equipment company that manufactures and markets gastroenterology and surgical products. The company’s products include esophy-x device and serosa-fuse fasteners. Its esophy-x device is used in reconstructing the gastroesoph …
  • Global Telecom Holding S.A.E.:企業の戦略・SWOT・財務情報
    Global Telecom Holding S.A.E. - Strategy, SWOT and Corporate Finance Report Summary Global Telecom Holding S.A.E. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆